Commentary

You have free access to this content

Human genome variation and pharmacogenetics†

  1. Bruce Gottlieb1,2,3,*

Article first published online: 10 MAR 2008

DOI: 10.1002/humu.20728

Issue

Human Mutation

Human Mutation

Special Issue: Focus on Pharmacogenetics

Volume 29, Issue 4, pages 453–455, April 2008

Additional Information

How to Cite

Gottlieb, B. (2008), Human genome variation and pharmacogenetics. Human Mutation, 29: 453–455. doi: 10.1002/humu.20728

Author Information

  1. 1

    Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada

  2. 2

    Department of Human Genetics, McGill University, Montreal, Quebec, Canada

  3. 3

    Department of Biology, John Abbott College, Ste Anne de Bellvue, Quebec, Canada

*Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote Ste. Catherine Road, Montreal, Quebec, Canada H3T 1E2

  1. †

    For the Focus Section on Pharmacogenetics

Publication History

  1. Issue published online: 10 MAR 2008
  2. Article first published online: 10 MAR 2008
  3. Manuscript Accepted: 18 DEC 2007
  4. Manuscript Received: 11 DEC 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (76K)

Keywords:

  • human genome variation;
  • pharmacogenetics;
  • pharmacogenomics;
  • genetic paradigm shift

Abstract

A recent HGVS-sponsored symposium has examined, for the first time, the possible effects of the discovery of very large and widespread amounts of human genome variation on the emerging fields of pharmacogenetics and pharmacogenomics. This article discusses the effects of the resultant paradigm shifts and raises a number of important questions that need to be considered in order to truly advance the field in a meaningful and significant way. Hum Mutat 29(4):453–455, 2008. © 2008 Wiley-Liss, Inc.

Get PDF (76K)